earnings
confidence high
sentiment negative
materiality 0.80
Johnson & Johnson Q3 sales up 5.2% to $22.5B; GAAP EPS down 34% to $1.11 on higher R&D and other charges
JOHNSON & JOHNSON
2024-Q3 EPS reported
$4.38
revenue$66,301,000,000
- Worldwide sales $22.47B (+5.2% reported, +6.3% operational); MedTech up 5.8%, Innovative Medicine up 4.9%.
- GAAP net earnings from continuing ops $2.69B ($1.11 diluted EPS), down 37.5% YoY; adjusted net earnings $5.88B ($2.42 adjusted EPS), down 13.3%.
- R&D expense jumped 43.7% to $4.95B (22.0% of sales); other expense net $1.80B vs $0.50B in prior year.
- GAAP effective tax rate 19.3% vs 17.4%; adjusted tax rate 19.3% vs 15.6%.
- Discontinued ops had no contribution vs $21.7B in prior year (related to Kenvue separation).